Sivik Global Healthcare LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 83.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,000 shares of the medical device company’s stock after purchasing an additional 9,100 shares during the period. Sivik Global Healthcare LLC’s holdings in DexCom were worth $2,861,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Principal Financial Group Inc. grew its stake in shares of DexCom by 7.9% during the first quarter. Principal Financial Group Inc. now owns 33,469 shares of the medical device company’s stock valued at $2,482,000 after purchasing an additional 2,459 shares during the last quarter. Bank of Montreal Can acquired a new position in DexCom in the second quarter valued at approximately $2,944,000. BNP Paribas Arbitrage SA lifted its holdings in DexCom by 41.9% in the second quarter. BNP Paribas Arbitrage SA now owns 6,115 shares of the medical device company’s stock valued at $581,000 after buying an additional 1,805 shares during the period. Dowling & Yahnke LLC lifted its holdings in DexCom by 7.4% in the second quarter. Dowling & Yahnke LLC now owns 62,855 shares of the medical device company’s stock valued at $5,970,000 after buying an additional 4,353 shares during the period. Finally, Accredited Investors Inc. acquired a new position in DexCom in the second quarter valued at approximately $225,000.
DXCM traded up $0.91 during mid-day trading on Monday, hitting $125.19. The stock had a trading volume of 173,067 shares, compared to its average volume of 1,616,208. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.43 and a current ratio of 4.71. The firm has a market cap of $11.04 billion, a PE ratio of -215.84 and a beta of 0.60. DexCom, Inc. has a 1-year low of $51.04 and a 1-year high of $152.14.
DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.29. The company had revenue of $266.70 million for the quarter, compared to analyst estimates of $242.72 million. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. DexCom’s revenue for the quarter was up 44.5% on a year-over-year basis. Equities analysts forecast that DexCom, Inc. will post -0.12 EPS for the current fiscal year.
In other news, EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $143.13, for a total transaction of $715,650.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 25,495 shares of the stock in a transaction on Monday, September 10th. The stock was sold at an average price of $143.62, for a total transaction of $3,661,591.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 148,009 shares of company stock worth $21,000,334. Company insiders own 1.80% of the company’s stock.
Several brokerages recently weighed in on DXCM. BidaskClub lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Oppenheimer restated a “buy” rating on shares of DexCom in a report on Wednesday, November 21st. Canaccord Genuity increased their price objective on shares of DexCom from $105.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Piper Jaffray Companies increased their price objective on shares of DexCom to $157.00 and gave the company an “overweight” rating in a report on Wednesday, November 7th. Finally, Morgan Stanley increased their price objective on shares of DexCom from $70.00 to $130.00 and gave the company an “equal weight” rating in a report on Friday, August 3rd. Eight analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. DexCom currently has a consensus rating of “Buy” and an average price target of $132.50.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: Coverage Ratio
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.